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Poster Session II 113who had HCT since 2001 with the use of 5 myeloablative condi-
tioning regimens: BuCY 6 Thymoglobulin, FluBu, or FluBu 1
Thymoglobulin with different doses of Flu designated Flu[1(120
mg/m2)]BuThy and Flu[2(250 mg/m2)]BuThy. Grafts consisted
of unmanipulated bone marrow or growth factor-mobilized blood
cells from related or unrelated donors, except for 9 patients who re-
ceived BuCY and mobilized blood cells from related donors that
were 90% depleted of T-cells. Donor chimerism in recipient blood
T-cells (CD3) and granulocytes (CD331) was measured at day 80
after HCT.
Patient characteristics in the 5 groups were similar: median age
49, 91% MDS or AML (64% high-risk), 51% unrelated donors,
88% PBSC, 59% HCT-CI $1. Donor chimerism of granulocytes
was complete by day 180 in all groups, but persistent mixed
T-cell chimerism was observed in certain groups. Compared to pa-
tients who received BuCY with unmanipulated allografts, the inci-
dence of mixed chimerism with .50% recipient T-cells was
higher among patients who received Flu, bone marrow grafts or
T-cell depleted grafts (e.g., Flu[1]BuThy: OR 14.5, p\ 0.0001).
Most patients with mixed chimerism at day 80 had full donor
T-cell chimerism at 1 yr after HCT, but some patients with
malignancy in complete remission at 3 yr continue to have per-
sistent mixed T-cell chimerism.
Compared to BuCY controls, improved outcomes with reduced
regimen-related toxicity were observed in the 22 patients who re-
ceived Flu[1]BuThy. After adjustment for age, disease risk, donor
type,HCT-CI and prior CMV infection in the recipient, the Flu[1]-
BuThy group had significantly lower rates of acute GvHD (HR
0.50, p 5 0.02), chronic GvHD (HR 0.31, p 5 0.003) and NRM
(HR 0.25, p 5 0.05), although relapse was not significantly in-
creased (HR 1.13, p 5 0.87) and overall survival was not signifi-
cantly improved (HR 5 0.60, p 5 0.19). In contrast, NRM and
survival in the Flu[2]BuThy and BuCY groups showed no statisti-
cally significant differences. In general, addition of thymoglobulin
for GvHD prophylaxis significantly reduced the incidence of
chronic GvHD. A prospective, randomized trial is needed to deter-
mine whether superior outcomes can be achieved after conditioning
with Flu[1]BuThy as compared with BuCy.305
THYMOGLOBULIN RABBIT ANTI-THYMOCYTE GLOBULINS (r-ATG)
INDUCES FASTER PLATELET RECOVERY AND DOES NOT SUPPRESS
GRANULOCYTE ENGRAFTMENT IN A NON-MYELOABLATIVE STEM
CELL TRANSPLANTATION SETTING
Shapira, M.Y., Resnick, I.B., Gesundeheidt, B., Bitan, M.,
Ackerstein, A., Samuel, S., Drey, L., Verkholevsky, Y., Slavin, S.,
Or, R. Hadassah – Hebrew University Medical Center, Jerusalem, Israel.
Introduction: : The role of anti thymocyte globulin in GVHD
prevention is well established, but it is also known that anti thymo-
cyte globulin induces leucopenia and thrombocytopenia and as such
might theoretically delay engraftment. Additionally, fast platelet
engraftment is a marker for good hematopoietic stem cell graft
function.We have prospectively compared the effect of Thymoglo-
bulin on engraftment of granulocytes and platelets following a single
non-myeloablative conditioning protocol in a randomized study.
Methods: 28 consecutive patients undergoing SCT were condi-
tioned with the NST protocol (I.V. fludarabine 30 mg/m2/day
(days -10 to -5) and I.V. busulfex (3.2 mg/kg on days 6 and 5),
with or without I.V. Thymoglobulin according to randomization
(days 4 to 1). Thymoglobulin dosing schedule: a cumulative dose
of 7.5 mg/kg r-ATG was given with the following program 0.5
mg/kg day -4, 2.0 mg/kg day -3, 2.5 mg/kg day -2, 2.5 mg/kg day
-1. Patients were followed for engraftment of leukocytes and plate-
lets. Results: only one patient rejected the graft (conditioned with-
out Thymoglobulin, NS). In 4 patients underlying disease
progression prevented engraftment of either ANC or platelets (2
per group). The median time to ANC engraftment was similar be-
tween the groups, 156 2.8 and 146 2.9 days for the Thymoglobu-
lin and control groups respectively (p5 0.21). However, themedian
time for platelet engraftment was significantly shorter in patients re-
ceiving Thymoglobulin as part of the conditioning. Platelet recov-
ery occurred 9.5 6 1.2 and 11 6 2.5 days for the Thymoglobulinand control groups respectively (p 5 0.018). Conclusions: In the
non-myeloablative setting, Thymoglobulin induces faster platelet
recovery and does not delay ANC engraftment.306
A COMPARISON OF MEASURED VS. CALCULATED CREATININE CLEAR-
ANCE AND THEIR LACK OF ASSOCIATION WITH RENAL REGIMEN RE-
LATED TOXICITY AFTER AUTOLOGOUS AND ALLOGENEIC BMT
Hahn, T., Dunford, L., Butler, B., Stento, N., Smiley, S., Battiwalla,M.,
McCarthy, P.L. Roswell Park Cancer Institute, Buffalo, NY.
Standard BMT eligibility criteria generally include glomerular
filtration rate (GFR) $50 ml/min for myeloablative and GFR
$40 ml/min for nonmyeloablative regimens. The most accurate,
but costly, method ofGFRmeasurement is urinary clearance ofmo-
lecular isotopes such as 99m Tc-DTPA. In BMT pts, GFR is com-
monly estimated by creatinine clearance in a 24 hour urine
collection (24 hr CrCl), a time-consuming and error-pronemethod.
4 equations incorporate different clinical variables to estimate CrCl:
Cockroft-Gault (CG), modified CG (mCG), Modification of Diet
in Renal Disease 1 (MDRD1) and MDRD2. The study objectives
were to determine which of 4 calculations consistently underesti-
mates measured CrCl pre-BMT and to determine if any were
correlated with renal regimen related toxicity (RRT). We retro-
spectively analyzed 100 consecutive allo (n 5 50) or auto (n 5 50)
BMT pts from 1/06 to 4/07 to compare measured CrCl with each
of the 4 formulas using linear regression and Wilcoxon signed
rank test. Renal RRT was defined using the Bearman scale: no in-
crease from baseline serum Cr (gr 0), any increase over baseline
(gr 1), doubling of baseline (gr 2), dialysis (gr 3), or death from renal
RRT (gr 4), with an incidence of 24%, 57%, 18%, 1% and 0%, re-
spectively. All 4 formulas were significantly (p\ .001) correlated to
measured CrCl with correlation coefficients (R) 5 .63 (CG), .61
(mCG), .50 (MDRD1) and .54 (MDRD2). When stratified by
gender, CG had the highest R for women (R 5 .679, p\ .001),
while MDRD1 had the highest for men (R 5 .40, p 5 .003).
MDRD1 consistently underestimated CrCl in the highest propor-
tion of pts (65%, p \ .001), compared to MDRD2 (65%, p 5
.001), mCG (54%, p5NS) and CG (33%, p 5 .001). Measured
CrCl, serum Cr, and all 4 calculations were not predictive of renal
RRT post-BMT. Significant univariate predictors of gr 2–3 renal
RRT were: alloBMT, reduced intensity/nonmyeloablative regi-
mens (RICNMA), KPS#80 and albumin#3.7 g/dL. In alloBMT,
BMI .35, KPS #80 and albumin #3.8 g/dL were significantly as-
sociated with gr 2–3 renal RRT, however in autoBMT baseline se-
rum Cr$1.1 was the only significant factor. Any of the 4 equations
can replace the 24 hr CrCl. CG is closest to, but overestimates CrCl
in 67% of pts. In comparison,MDRD1 consistently underestimates
CrCl in 65%. Larger analyses may better define subgroups at risk
for renal RRT. Our results suggest a lower CrCl threshold may
be acceptable for BMT due to the relatively low gr 2–4 renal
RRT incidence observed.307
MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN 424
PATIENTS USING BUSULFAN AND CYCLOPHOSPHAMIDE
Floisand, Y.1, Tjonnfjord, G.E.1, Gedde-Dahl d.y., T.1, Heldal, D.1,
Egeland, T.2, Dybedal, I.1, Holme, P.A.1, Brinch, L.C.1. 1Rikshospitalet
University Hospital, Oslo, Norway; 2Rikshospitalet University Hospital,
Oslo, Norway.
Background/Aims: From 1985 to 2007, 424 adult patients re-
ceived Busulfan Cyclophosphamide (Bu4Cy2) as conditioning regi-
men before allogeneic stem cell transplantation in our institution.
In this study we analyzed this group with regard to overall survival,
LFS, TRM and the incidence of complications.
Patient Material/Methods: 424 patients underwent ASCT;
43% female (N 5 185) and 57% male(N 5 239). Median age was
39.9 y (15.4–60.7). 263 patients (62%) received transplants from
family donors and 161 (38%) from matched unrelated donors
